This guidance shall be published in Volume 9 of The rules .. ANNEX I – VEDDRA list of Clinical Terms (EMEA/CVMP/ /Final). in consultation with the European Medicines Agency (EMEA – “the Agency”) Structure of Volume 9A Part I deals with Guidelines for. Flag of European Union portal · Other countries · Atlas · v · t · e. EudraLex is the collection of rules and regulations governing medicinal products in the European Union. Contents. 1 Volumes; 2 Directives; 3 See also; 4 References; 5 External links. Volumes. EudraLex consists of 10 volumes: Volume 9 – Pharmacovigilance.
|Published (Last):||25 August 2008|
|PDF File Size:||3.62 Mb|
|ePub File Size:||4.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
There is no structure prescribed for the recording system, although data protection regulations must be complied with when handling patients’ personal details.
He or she is, among other things, responsible for submitting reports of adverse drug reactions and PSURs, for periodic research through literature, for personnel training and acts as the central contact for the authorities. The aim is to handle and volumd data in such a way that it cannot be lost fmea falsified and to enable changes to be traced audit trail.
It is recommended that the Marketing Authorisation Holder conduct audits. This practice is permitted explicitly in Volume 9A part 1, point 1. Therefore, the SOP’s description of the interfaces between the sources and the processors of PV-related data is particularly important when service providers are engaged on multiple levels.
The preparation and updating of SOPs and of accompanying process-specific descriptions are complex. These points must also be defined in the SOP.
Experienced service providers with an “unbiased view” may identify scope for improvement more quickly. The EudraLex Volume 9A incorporated the obligation to include a “Detailed Description of the Pharmacovigilance System” in every marketing authorisation application module 1. It is much less common for these drugs to have serious adverse reactions. Receipt of Spontaneous Reports Processing reports of suspected cases of adverse drug reactions is a central issue of any PV system.
The authorities expect a brief description of the nature of these agreements with the relevant assignment of responsibilities. A flow chart should be generated for the DDPS, showing the central processing steps within the company for an incoming report of a suspected adverse drug reaction cf. The PV system, of course, also includes storage of the compiled documents.
The possible disadvantages identified in outsourcing are a potential dependence on external third parties or upon the reliability of their work.
The purpose of the 9aa Description of the Pharmacovigilance System DDPS which is formalised in Volume 9A is to describe the actual safety-monitoring practice followed in the company. It is imperative that tasks and interfaces emes clearly defined. It should be noted that there is no fundamental difference between a contractual commitment to a service provider and being committed to changing employees through employment contracts.
In the event of leave, illness or time off, an acting QPPV must be designated in writing. ICSRs represent volumd interesting yet sensitive area in the cooperation between pharmaceutical companies and external service providers. Post Approval Safety Data Management: There should also be a cross-reference to a training SOP, which is used as a basis for training all the employees in question on how to process spontaneous reports. The DDPS also contains a description of the organisational structure.
Documented Procedures A flow chart should be generated for the DDPS, showing the central processing steps within the company for an emfa report of a suspected adverse drug reaction cf. Service providers may handle spontaneous reports instead of the Marketing Authorisation Holder. 9z, for example, may take the form of co-marketing contracts which include a contractual provision on reporting spontaneous incidents.
How is compliance with the timescale regulated? This should serve to document the emez that future Marketing Authorisation Holders have an effective safety system for their medicinal products in place, or —if they have not already done so— are able to establish such e,ea system.
The SOPs should generally be made available within two days, on request from the competent authority. There is no period of time stipulated for document retention e.
Qualified Person Responsible for Pharmacovigilance The Marketing Authorisation Holder is responsible for the safety of its products and must undertake to commission a Qualified Person for Pharmacovigilance QPPV to monitor the safety of medicinal products and to provide this person with the requisite resources to do so.
Anja op de Bekke Dr. It is important to remember, for example, that even where medicinal products are only approved nationally for example in Germany, suspected serious and unexpected adverse drug reactions experienced in non-EU member states still have to be reported electronically to the EMEA’s EudraVigilance database by specially trained personnel.
There is now a wide array of highly skilled services available on the market, including auditing, commissions to submit electronic reports of suspected adverse drug reactions to the EMEA, the provision of Qualified Persons for Pharmacovigilance and the implementation of complete PV systems.
Whilst these sorts of formalities may seem less unusual for the Rx industry, they represent much more in the way vo,ume new ground for the OTC industry. As in other situations where tasks are outsourced, the Marketing Authorisation Holder takes on a certain dependence: